Challenge Grant: Development of Nanoparticle-based Immunotherapy Against Refractory Cancer

• Return to Project List

Summary

Cancer immunotherapy is a potentially curative therapeutic for advanced cancer. In particular, chimeric antigen receptor (CAR) T-cell therapy showed marked efficacy against relapsed and refractory hematologic cancers and has already been in the clinic. However, the efficacy of CAR-T cell therapy for other cancers is still limited. T cells need to be optimally primed by antigen presenting cells to migrate to the solid tumor tissue through costimulation and cytokines, which are not necessarily proved for infused CAR-T cells. In this study, we will use a nanoparticle platform that induces complex immune cell activation signals to prime CAR-T cells in vivo. The developed particle will function as artificial antigen presenting system to allow CAR-T cells to infiltrate into tumor tissue.

SDGs

Project Members

About Project Members, Researchers

Note: ◎ indicates the project leader

Name	Affiliation	Position	Field of Specialization/Research Interests
◎ Yuki Kagoya	School of Medicine	Professor	Cancer immunology and immunotherapy
Teruhiko Matsubara	Faculty of Science and Technology	Associate Professor	Nanoengineering of cells
Masato Tsutsui	Faculty of Science and Technology	Assistant Professor	Nanoengineering of cells
Thao Nguyen	School of Medicine	Project Researcher	Cancer immunology and immunotherapy
Yang Li	Graduate School of Medicine	Doctoral Program	Cancer immunology and immunotherapy